Ivermectin: Still on a Losing Streak as COVID-19 Treatment
WASHINGTON — There were no differences in relief from mild-to-moderate COVID-19 symptoms for patients on ivermectin versus placebo, according to the ongoing ACTIV-6 trial. Among >1,000 vaccinated and unvaccinated patients, the median time to recovery was 12 days for those in the ivermectin group and 13 days in the placebo group, reported Matthew McCarthy, MD, […]
Finerenone improves outcomes in patients with mild-to-moderate kidney disease and diabetes
Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. That’s the finding of late breaking research presented in a Hot Line session today at ESC Congress 20211 and published in the New England Journal of Medicine2. Diabetic kidney disease develops in approximately 40% of patients […]